CPB Ljubljana 2018 course book

NASOPHARYNX BT BOOST. IVO EXPERIENCE

• 30 patients (2000-2017) • 49 years old (31-72), men 83% • T1 70%, T2 20%, Tx 10% • EBRT median 60 Gy to NP + BT 4 x 3Gy o 3 x 3,5Gy • 67% Chemotherapy • 78 meses FU (mediana)

• 5-year local control 95% 1 local rec (parapharyx) T2N2 • 5-year regional control 92% (2) • 5-year distant M+ free 84% (4 M+)